NO20055907L - Fremgangsmate for behandling av en angstforstyrrelse - Google Patents

Fremgangsmate for behandling av en angstforstyrrelse

Info

Publication number
NO20055907L
NO20055907L NO20055907A NO20055907A NO20055907L NO 20055907 L NO20055907 L NO 20055907L NO 20055907 A NO20055907 A NO 20055907A NO 20055907 A NO20055907 A NO 20055907A NO 20055907 L NO20055907 L NO 20055907L
Authority
NO
Norway
Prior art keywords
disorder
treating
anxiety disorder
adenosine
receptor antagonist
Prior art date
Application number
NO20055907A
Other languages
English (en)
Norwegian (no)
Inventor
Hiroshi Kase
Naoki Seno
Shizuo Shiozaki
Minoru Kobayashi
Junya Kase
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO20055907L publication Critical patent/NO20055907L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NO20055907A 2003-06-10 2005-12-13 Fremgangsmate for behandling av en angstforstyrrelse NO20055907L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US53279303P 2003-12-24 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (1)

Publication Number Publication Date
NO20055907L true NO20055907L (no) 2005-12-13

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055907A NO20055907L (no) 2003-06-10 2005-12-13 Fremgangsmate for behandling av en angstforstyrrelse

Country Status (15)

Country Link
US (2) US8202869B2 (enExample)
EP (1) EP1631294B1 (enExample)
JP (1) JP4778894B2 (enExample)
KR (1) KR20060037252A (enExample)
CN (1) CN1787821A (enExample)
AT (1) ATE481101T1 (enExample)
AU (1) AU2004244906A1 (enExample)
BR (1) BRPI0411120A (enExample)
CA (1) CA2528710C (enExample)
CO (1) CO5640121A2 (enExample)
DE (1) DE602004029160D1 (enExample)
EA (1) EA200501924A1 (enExample)
MX (1) MXPA05013148A (enExample)
NO (1) NO20055907L (enExample)
WO (1) WO2004108137A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20090082341A1 (en) * 2007-07-23 2009-03-26 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
JOP20200342A1 (ar) 2018-07-05 2020-12-30 Incyte Corp مشتقات بيرازين مدمجة كمثبطات a2a/a2b
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2051772T3 (es) * 1986-09-30 1994-07-01 Ciba Geigy Ag 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
PT628311E (pt) 1992-07-08 2002-09-30 Kyowa Hakko Kogyo Kk Derivado de xantina com actividade antidepressiva
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
BR9914040A (pt) 1998-09-22 2002-01-15 Kyowa Hakko Kogyo Kk Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios
WO2000069464A1 (en) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Novel use
JP4574112B2 (ja) * 2000-05-26 2010-11-04 シェーリング コーポレイション アデノシンａ２ａレセプターアンタゴニスト
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) * 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
WO2003043637A1 (en) * 2001-11-20 2003-05-30 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Also Published As

Publication number Publication date
CN1787821A (zh) 2006-06-14
US20060281770A1 (en) 2006-12-14
ATE481101T1 (de) 2010-10-15
AU2004244906A1 (en) 2004-12-16
MXPA05013148A (es) 2006-03-17
US8202869B2 (en) 2012-06-19
WO2004108137A1 (en) 2004-12-16
CO5640121A2 (es) 2006-05-31
US8592420B2 (en) 2013-11-26
CA2528710C (en) 2012-04-17
EA200501924A1 (ru) 2006-06-30
BRPI0411120A (pt) 2006-07-18
DE602004029160D1 (enExample) 2010-10-28
JP4778894B2 (ja) 2011-09-21
KR20060037252A (ko) 2006-05-03
CA2528710A1 (en) 2004-12-16
EP1631294A1 (en) 2006-03-08
US20120232089A1 (en) 2012-09-13
EP1631294B1 (en) 2010-09-15
JP2006527264A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
WO2009061924A3 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2005074607A3 (en) Method of treating hemolytic disease
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
TW200507840A (en) Method of treating multiple myeloma
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
AR042890A1 (es) Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
NO20083034L (no) Farmasoytiske formuleringer av escitalopram med modifisert og pulserende frigivelse
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application